相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
Andrea Sartore-Bianchi et al.
CANCER RESEARCH (2009)
PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer
Hans Prenen et al.
CLINICAL CANCER RESEARCH (2009)
Association of GUCY2C Expression in Lymph Nodes With Time to Recurrence and Disease-Free Survival in pN0 Colorectal Cancer
Scott A. Waldman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
Carsten Bokemeyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Previstage™ GCC Colorectal Cancer Staging Test A New Molecular Test to Identify Lymph Node Metastases and Provide More Accurate Information about the Stage of Patients with Colorectal Cancer
Marilyn R. Carlson
MOLECULAR DIAGNOSIS & THERAPY (2009)
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
Jolien Tol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab:: A fluorescent in situ hybridization study
Nicola Personeni et al.
CLINICAL CANCER RESEARCH (2008)
Don quixote and the quest for personalized medicine
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Determinants of RASistance to anti-epidermal growth factor receptor agents
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
Astrid Lievre et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
W. De Roock et al.
ANNALS OF ONCOLOGY (2008)
Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy
Ido Amit et al.
MOLECULAR SYSTEMS BIOLOGY (2007)
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
M. Frattini et al.
BRITISH JOURNAL OF CANCER (2007)
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
Shirin Khambata-Ford et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
F. Di Fiore et al.
BRITISH JOURNAL OF CANCER (2007)
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies
Silvia Benvenuti et al.
CANCER RESEARCH (2007)
Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study
George P. Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan
Maguy Del Rio et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response
Sherene Loi et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
Colorectal cancer and genetic alterations in the Wnt pathway
S. Segditsas et al.
ONCOGENE (2006)
A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer
S. Popat et al.
ANNALS OF ONCOLOGY (2006)
Stage II colon cancer prognosis prediction by tumor gene expression profiling
Alain Barrier et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The epidermal growth factor receptor pathway: A model for targeted therapy
Maurizio Scaltriti et al.
CLINICAL CANCER RESEARCH (2006)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients
JL Westra et al.
ANNALS OF ONCOLOGY (2005)
Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients
JL Westra et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Role of genomic markers in colorectal cancer treatment
WL Allen et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Metastatic transcriptional pattern revealed by gene expression profiling in primary colorectal carcinoma
A D'Arrigo et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Molecular staging for survival prediction of colorectal cancer patients
S Eschrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
M Moroni et al.
LANCET ONCOLOGY (2005)
SMAD4 as a prognostic marker in colorectal cancer
H Alazzouzi et al.
CLINICAL CANCER RESEARCH (2005)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract
R Birbe et al.
HUMAN PATHOLOGY (2005)
Systematic review of microsatellite instability and colorectal cancer prognosis
S Popat et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis
S Popat et al.
EUROPEAN JOURNAL OF CANCER (2005)
Opinon - Cancer as a robust system: implications for anticancer therapy
H Kitano
NATURE REVIEWS CANCER (2004)
Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters
F Bertucci et al.
ONCOGENE (2004)
Gene expression profiling of colorectal cancer and metastases divides tumours according to their clinicopathological stage
A Koehler et al.
JOURNAL OF PATHOLOGY (2004)
Colon cancer survival rates with the new American Joint Committee on cancer sixth edition staging
JB O'Connell et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer
CM Ribic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Role of DNA mismatch repair defects in the pathogenesis of human cancer
P Peltomäki
JOURNAL OF CLINICAL ONCOLOGY (2003)
Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer
AS Schrohl et al.
MOLECULAR & CELLULAR PROTEOMICS (2003)
Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer:: A national cancer institute-national surgical adjuvant breast and bowel project collaborative study
CJ Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Thymidylate synthase expression in colorectal cancer:: A prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy
D Edler et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
p53 nuclear accumulation and multiploidy are adverse prognostic factors in surgically resected stage II colorectal cancers independent of fluorouracil-based adjuvant therapy
S Buglioni et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2001)
Molecular predictors of survival after adjuvant chemotherapy for colon cancer.
T Watanabe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
p53 Gene mutation, microsatellite instability and adjuvant chemotherapy: Impact on survival of 388 patients with Dukes' C colon carcinoma
H Elsaleh et al.
ONCOLOGY (2000)
分享论文
